ESL – 0106 M5: Supplementary Reading: Genetics, the Human Genome Project, Drug Breakt…

english exercise and need the explanation and answer to help me learn.

M5: Supplementary Reading: Genetics, the Human Genome Project, Drug Breakt…

Reading Summary is due by 6:30 pm, October 16.
Perform a database search in order to find an article of 750+ words about this week’s topics: Genetics, Genetic Research, the Human Genome Project. Read the article and answer the following questions in paragraph form in a Word document. Save the article as a PDF and link it into your Word Document.
Use the four reading strategies discussed in class to choose and to read your article (Remember, skim for length, structure, basic content before you commit to the article!). Put it in MLA format and include Work Cited information at the end of your assignment. Attach the assignment here as instructed in “Blackboard How Tos” in the “Start Here” content area.
1. Write your main idea sentence first. Don’t forget to include the author or the article and claim signal words.
2. What major support does the writer include to support the claim? Mention at least three key pieces of evidence (support).
3. How is the article organized? problem/solution, classification, compare/contrast, cause/effect, definition?
4. Why did you choose this article?
5. What are your thoughts about the writer’s claim? Do you agree? Disagree? Why?
Include a Work Cited information at the the end of the paragraph!
View Rubric
Reading Response Scoring Tool
Reading Response Scoring Tool
Criteria Ratings Pts
Formatting and Mechanics
view longer description
10 pts
Great!
Assignment is in MLA format. There are few mechanical errors or grammatical structures that interfere with coherence.
9 pts
Not Bad!
Assignment may not be in correct in MLA format. There may be mechanical errors or grammatical structures that interfere with coherence.
5 pts
Uh oh! See me!
Assignment may be sloppy or lack coherence.
/ 10 pts
Content
view longer description
15 pts
Great!
Assignment identifies key elements of citation including author, date, and source of publication. Assignment clearly and thoroughly summarizes key content.
11 pts
Not Bad!
Assignment may or may not identify all key elements of citation including author, date, and source of publication. Summary may miss some key content or may not appropriately paraphrase.
7 pts
Uh oh! See me!
Assignment is not completed as instructed.
/ 15 pts
Main Idea
view longer description
5 pts
Great!
Writer accurately identifies and paraphrases the main idea of the reading.
4 pts
Not Bad!
Writer does not accurately identify and/or paraphrase the main idea of the reading.
0 pts
Uh oh! See me!
No attempt has been made to paraphrase the main idea.
/ 5 pts
Requirements:
Disclaimer: This is a machine generated PDF of selected content from our products. This functionality is provided solely for yourconvenience and is in no way intended to replace original scanned PDF. Neither Cengage Learning nor its licensors make anyrepresentations or warranties with respect to the machine generated PDF. The PDF is automatically generated “AS IS” and “ASAVAILABLE” and are not retained in our systems. CENGAGE LEARNING AND ITS LICENSORS SPECIFICALLY DISCLAIM ANYAND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY,ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULARPURPOSE. Your use of the machine generated PDF is subject to all use restrictions contained in The Cengage LearningSubscription and License Agreement and/or the Gale OneFile: Health and Medicine Terms and Conditions and by using themachine generated PDF functionality you agree to forgo any and all claims against Cengage Learning or its licensors for your use ofthe machine generated PDF functionality and any output derived therefrom.Reports Outline COVID-19 Research from Central ResearchInstitute of Epidemiology (Efficacy and safety of molnupiravirin adult outpatients with COVID-19).Date:July 29, 2023 From:Obesity, Fitness & Wellness WeekPublisher:NewsRX LLCDocument Type:Article Length:712 wordsFull Text: 2023 JUL 29 (NewsRx) — By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week — Current study results onCOVID-19 have been published. According to news originating from the Central Research Institute of Epidemiology by NewsRxcorrespondents, research stated, “One of the basic principles for the treatment of COVID-19 patients is the early initiation of etiotropictherapy. The evidence base for assessment of the efficacy and safety of antivirals for COVID-19 continues to expand with newclinical trials. One of the promising etiotropic medications is molnupiravir.”Our news reporters obtained a quote from the research from Central Research Institute of Epidemiology: “To evaluate the efficacyand safety of molnupiravir (Esperavir) in outpatients with COVID-19. This randomized comparative open-label clinical study wasconducted from December 1, 2021 to March 11, 2022 in 12 research centers in the Russian Federation. The study involved 240outpatients with mild and moderate COVID-19. The mean age of patients was 43.5 years; 70,0% (168/240) of the patients hadcomorbidities, mainly obesity grade II and arterial hypertension. The outpatients were treated with molnupiravir (Esperavir,PROMOMED RUS LLC, Russia) in 4 capsules 200 mg twice daily (every 12 hours), with the single dose being 800 mg and the dailydose 1600 mg. Duration of treatment was 5 days. The patients were followed up for 28 days. The patients in the standard treatmentgroup (n = 120) received antiviral therapy recommended for outpatients by the provisional guidelines effective at the time of thestudy. Pathogenetic and symptomatic therapy in both groups was comparable. The results of the clinical study in 240 outpatients withmild or moderate COVID-19 showed that molnupiravir at a dose of 800 mg twice daily for 5 days significantly reduced (by 4-hold atdays 1415 of the follow-up) the risk of disease progression to more severe course, compared with the standard therapy group (2.5%(3/120) and 10.0% (12/120) of patients; p = 0.0149.) By days 67 of the follow-up, the virus had been eliminated in 71.67% of thepatients treated with the study drug and only in 58.3% (70/120) of the patients in the standard therapy group. Complete clinicalrecovery at days 67 was achieved in 19.2% (23/120) of the patients in the molnupiravir group, compared to 5.8% (7/120) in thestandard therapy group. Compared to the standard therapy, treatment with molnupiravir also significantly reduced the frequency andseverity of the disease symptoms, such as cough and change in odor or taste perception over the last 24 hours, already at 67 daysafter the start of treatment. Molnupiravir treatment was well tolerated, most adverse events were mild. There were no cases of drugwithdrawal or dose modification of the study drug due to adverse events.”According to the news editors, the research concluded: “The results of the clinical study of antiviral agent molnupiravir (Esperavir)have proven its benefits over standard therapy in outpatients with mild and moderate COVID-19 in terms of the disease worseningrisk reduction and hospitalization, the rate of viral elimination, the changes in symptoms severity over time, improvement of thepatients general status and clinical condition and reduction of COVID-19 complications both in patients without and with risk factorsfor severe COVID-19 outcomes. The results of this study demonstrated a favorable safety profile of molnupiravir in COVID-19patients.”For more information on this research see: Efficacy and safety of molnupiravir in adult outpatients with COVID-19. Al’manahKliniceskoj Mediciny, 2023,51(2):86-98. (Al’manah Kliniceskoj Mediciny – http://www.almclinmed.ru). The publisher for Al’manahKliniceskoj Mediciny is MONIKI.A free version of this journal article is available at https://doi-org.pgcc.idm.oclc.org/10.18786/2072-0505-2023-51-014.Our news journalists report that more information may be obtained by contacting Natalia Y. Pshenichnaya, Central Research Instituteof Epidemiology.Keywords for this news article include: Central Research Institute of Epidemiology, Viral, COVID-19, Virology, Hospitals, SARS-CoV-2, RNA Viruses, Epidemiology, Clinical Research, Disease Attributes, Disease Progression, Drugs and Therapies, Health and
Medicine, Risk and Prevention, Clinical Trials and Studies, Severe Acute Respiratory Syndrome Coronavirus 2.Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2023, NewsRx LLCThe citation for this news report is: NewsRx. Reports Outline COVID-19Research from Central Research Institute of Epidemiology(Efficacy and safety of molnupiravir in adult outpatients with COVID-19). Obesity, Fitness & Wellness Week. July 29, 2023; p 277.Copyright: COPYRIGHT 2023 NewsRX LLC http://www.newsrx.com/newsletters/Obesity,-Fitness-and-Wellness-Week.htmlSource Citation (MLA 9th Edition)    “Reports Outline COVID-19 Research from Central Research Institute of Epidemiology (Efficacy and safety of molnupiravir in adultoutpatients with COVID-19).” Obesity, Fitness & Wellness Week, 29 July 2023, p. 277. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A758204727/HRCA?u=pgcc_main&sid=bookmark-HRCA&xid=6e301066. Accessed 11 Oct. 2023.Gale Document Number: GALE|A758204727

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *